← Back to Search

Behavioral Intervention

Machine Learning for Smoking Cessation

N/A
Waitlist Available
Led By Emily Hebert, DrPH
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group

Summary

This trial will test how well a machine learning-based intervention can help people quit smoking.

Who is the study for?
This trial is for individuals who want to quit smoking and are currently smoking more than 5 cigarettes a day. They should have no issues with using nicotine patches, be able to read at a basic level (REALM-SF score ≥4), and own an Android phone (version 5.2+) on which they can install the InsightTM mHealth app.
What is being tested?
The study tests a personalized intervention that uses machine learning to predict when someone might lapse in their attempt to quit smoking. It includes interviewing-based counseling, nicotine patches, and monitoring through an Android Wear smartwatch.
What are the potential side effects?
Potential side effects may include skin irritation from the nicotine patch and typical withdrawal symptoms from quitting smoking such as irritability, cravings, or difficulty concentrating.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Adaptive Treatment plus usual careExperimental Treatment4 Interventions
Group II: Usual careActive Control3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotine
FDA approved

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,586 Previous Clinical Trials
3,328,470 Total Patients Enrolled
The University of Texas Health Science Center, HoustonLead Sponsor
946 Previous Clinical Trials
344,389 Total Patients Enrolled
Emily Hebert, DrPHPrincipal InvestigatorThe University of Texas Health Science Center, Houston

Media Library

Adaptive Treatment (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04839198 — N/A
Smoking Cessation Research Study Groups: Adaptive Treatment plus usual care, Usual care
Smoking Cessation Clinical Trial 2023: Adaptive Treatment Highlights & Side Effects. Trial Name: NCT04839198 — N/A
Adaptive Treatment (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04839198 — N/A
Smoking Cessation Patient Testimony for trial: Trial Name: NCT04839198 — N/A
~0 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top